sachs associates   2nd ANNUAL
Sachs Cancer Bio Partnering &
Investment Forum

Promoting Public & Private Sector Collaboration & Investment
in Drug Development
    19th March 2014 • New York Academy of Sciences • USA
Register Now
To Exhibit
To Present
sachs sachs sachs sachs sachs sachs sachs
Biotech i Europe Investor Forum
sachs sachs
Companies Presenting at the 2014 Forum include:
Actinium Pharmaceuticals, Inc.
Argos Therpeutics, Inc
Avax Technologies, Inc
BerGenBio AS
Biovest International, Inc.
MaxCyte, Inc.
Navidea Biopharmaceuticals
Novogen Ltd
NuvOx Pharma, LLC
OncoSec Medical, Inc.
Prolong Pharmaceuticals, LLC
Therapure Biopharma Inc.

Emerging Presenting Companies 2014 include:
Adherex Technologies, Inc.
Fusion Pharma, LLC
Gem Pharmaceuticals
Incuron LLC
Intensity Therapeutics, Inc.
Inthera Bioscience AG
Melanovus Oncology
Neonc Technologies, Inc.
Providus Therapeutcis, Inc.
Quantum Pharmaceuticals
Rexahn Pharmaceuticals
RGenix, Inc.
Sopherion Therapeutics, LLC
Companies Who Presented at the 2013 Forum Included:
Aileron Therapeutics, Inc.
AnaptysBio, Inc
Argos Therpeutics, Inc
Atossa Genetics
BioCancell Ltd.
BioLineRx Ltd.
Churchill Pharmaceuticals
Constellation Pharmaceuticals
CureVac GmbH
Dicerna Pharmaceuticals
Etubics Corporation
immatics biotechnologies GmbH
ImmunoGen, Inc
Life Science Nation
MacroGenics, Inc
Melanovus Oncology
MiNA Therapeutics
Oncolix, Inc.
OncoSec Medical Incorporated
Oxford BioTherapeutics
RAMOT at Tel Aviv University
Rescue Therapeutics, Inc.
Sialix, Inc.
Sorrento Therapeutics
to-BBB technologies BV
TVAX Biomedical, Inc.



The 2nd Annual Sachs Cancer Bio Partnering & Investment Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering and funding/investment. We expect around 200 delegates and there is an online meeting system and meeting facilities to make the event transactional. There will also be a track of about 30 presentations by listed and private biotechnology companies seeking licensing/investment.


The 2nd Annual Sachs Cancer Bio Partnering & Investment Forum will cover the following topics in the program:

  • Advances in Translational Research
  • Strategies for Small Molecule and Biologicals Drug Development
  • Deal Making
  • Public & Private Partnerships
  • Diagnostics
  • Immunotherapies and Cancer Vaccines
  • Case Study

Confirmed Speakers & Chairs include:
Anne Altmeyer, VP, Oncology Business Development & Licensing,
Novartis Pharmaceuticals Corporation
Beth Jacobs, Managing Partner, Excellentia Global Partners
Boris Peaker, Executive Director, Biotechnology Equity Research, Oppenheimer & Co. Inc.
Brian A. Sherer, Group Leader, Medicinal Chemistry, EMD Serono
Carole Nuechterlein, Head Roche Venture Fund, F.Hoffmann-La Roche Ltd. - Roche Venture Fund
Cornelia Reininger, CMO, Navida Biopharmaceuticals
Daryl Mitteldorf, Executive Director, Global Prostate Cancer Alliance
David Vera, Professor of Radiology and Co-Director,
UCSD In Vivo Cancer and Molecular Imaging Center
Dennis J. Purcell, Senior Managing Partner, Aisling Capital LLC
Doug Plessinger, Vice President of Clinical and Medical Affairs, Argos Therapeutics, Inc.
Dov Hass, Associate, Morgan, Lewis & Bockius LLP
Elizabeth Bachert, Sr. Director, Pfizer Inc.
Florian Schodel, Owner, Philimmune LLC
Francisco Civantos, Co-Director, Division of Head and Neck Surgery,
University of Miami Health System
Guillaume Vignon, Director Business Development Oncology – Global Business Development and Licensing, EMD Serono
Harry Glorikan, Managing Director, Strategy, Scientia Advisors,
a Precision for Medicine Company

James Mulé, Associate Center Director, Moffit Cancer Center
Kareem Reda, Associate Director, Business Development, Celgene
Keith Knutson, Program Director/Full Member/Principal Investigator, Cancer Vaccines and Immunotherapy Program, Vaccine and Gene Therapy Institute of Florida
Kristina Khodova, Head of Oncology Projects, Biomed Cluster, Skolkovo Foundation
Louis J. DeGennaro, Interim Prsident and CEO/Chief Mission Officer,
The Leukemia and Lymphoma Society
Louise M. Perkins, Chief Science Officer, Melanoma Research Alliance
Mara Goldstein, Managing Director & Senior Biotechnology Analyst, Cantor Fitzgerald
Martin Buckland, CBO Astex Pharmaceuticals and SVP, Corporate Development,
Otsuka Pharmaceutical Development & Commercialization, Inc.
Michael Goldberg, Managing Partner, Montaur Capital
Dr Michael J. Donovan, Vice Chair of Pathology, The Mount Sinai Research Venter
Nathan Tinker, Executive Director, NewYorkBIO
Nicholas Dracopoli, Vice President, Head, Biomarkers and Chief Scientific Officer, Next Generation Circulating Tumor Cell Technology, Janssen Research & Development LLC
Peter Hoang, Managing Director, Office of Innovations, Technology Based Ventures, The University of Texas MD Anderson Cancer Center
Philip Gotwals, Executive Director, Oncology Research Collaborations, Novartis Institutes for BioMedical Research, Inc.
Rick Guidotti, Founder and CEO, Positive Exposure
Robert Petit, Chief Scientific Officer, Advaxis
Stephen Brozak, Managing Partner and President, WBB Securities, LLC
Steven Young, President & COO, Addario Lung Cancer Medical Institute
Stuart Barich, Managing Director, Oppenheimer & Co. Inc.
Thomas H. Tulip, President and Chief Business Officer, Navidea Biopharmaceuticals
Tim Herpin, Vice President, Head of Transactions (UK), Business Development, AstraZeneca
Vikas Sharma, Director, Business Development, Rexahn Pharmaceuticals
Walter M. Capone, President, Multiple Myeloma Research Foundation

View the full list of 2013 Forum Speakers & Chairs >>


Presenting Opportunities for Biotech, Pharmaceutical companies  and Patient Advocacy Groups

Presenting at the forum offers excellent opportunities to showcase activities and highlight investment and partnership opportunities. Biotech companies will be able to communicate investment and licensing opportunities. These are for both public and private companies. The audience is comprised of financial and industry investors. These are streamed 15 minute presentations. The patient advocacy presentations are 30 minutes.

Sachs forums are recognised as the leading international stage for those interested in investing in the biotech and life science industry and are highly transactional. They draw together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharmas. The Boston forum provides the additional interaction with the academic/scientific and patient advocacy communities.

Sponsorship and Exhibition

Sachs Associates has developed an extensive knowledge of the key individuals operating within the European and global biotech industry. This together with a growing reputation for excellence puts Sachs Associates at the forefront of the industry and provides a powerful tool by which to increase the position of your company in this market.

Raise your company’s profile directly with your potential clients. All of our sponsorship packages are tailor made to each client, allowing your organisation to gain the most out of attending our industry driven events.

To learn more about presenting, exhibition or sponsorship opportunities, please contact
Mina Orda + 44 (0)203 463 4890 or by email: Mina Orda.

2014 Attendees now online.
View >>>
Conference Guide:
Click the cover below to download the full conference guide.
Sachs - 2nd Annual Sachs Cancer Bio
Sachs on TwitterFollow us on Twitter @SachsAssociates
To learn more about presenting, exhibition or sponsorship opportunities, please contact Mina Orda
+ 44 (0)203 463 4890 or by email: Mina Orda.
For special rates for conference accommodation contact Melanie Lozano at melanie.lozano@whotels.com or call 646-826-8627 and she will be happy to assist you with your booking.
  Pharma Licensing
  Groups attending
  the Forum include:
AstraZeneca Celgene Corporation Janssen Research & Development Merck & Co Merck Serono Novartis Novo A/S Pfizer Inc. Takeda Pharmaceuticals International Teva Pharmaceutical Industries Ltd
  Financial Advisory/
  Investors attending
  the Forum include:
A.M.Pappas & Associates/Pappas Ventures
Advent Capital Management
Advent Healthcare Ventures
AE Smith Associates
Aisling Capital
Akemi Capital
Altius Strategy Consulting
Apache Capital Management
APS International
Arcus Ventures
Bluecloud Healthcare
Cantor Fitzgerald
Connectis Ventures
Delwar Capital
Eachwin Capital LP
Excellentia Global Partners
Extera Partners
F. Hoffmann-La Roche AG Roche Venture Fund
GC Capital Partners
GC Finance
Griffin Securities
Hercules Technology Growth Capital,
J&J Innovation Center-Boston
Jefferies & Co, Inc.
JHS Capital
Jina Ventures Inc.
Knoll Capital Management
Ladenburg Thalmann & Co Inc
Landmark Angels, Inc.
Lane Montgomery
Lazar Partners
Livingston Securities
Maxim Group
MedImmune Ventures Inc.
MedPro Investors LLC
Mehta Partners LLC
Mitchell and Sullivan Capital
MLV & Co.
MRL Ventures, Merck & Co.,Inc.
Novo A/S
Numoda Corporation
Oppenheimer & Co. Inc.
Oxford Finance LLC
Polar Star Ventures
Rockport Venture Partners
Silicon Valley Bank
Sphera Global Healthcare Fund
Stanphyl Capital
Steven Katz & Asscoiates, Inc.
Structured BioEquity
Styvesant Capital Management Corp.
The Channel Group
Third Rock Ventures
Transnational Capital Corp
Vivant Holdings
WBB Capital
WBB Securities, LLC Weiss Multi-Strategy Advisers
World Tech Ventures, LLC
Yorkville Advisors, LLC
  Meeting Scheduler
1-2-1 Meeting system